Indapta Therapeutics
Matthew C. is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as Director of Preclinical and Translational Research at Indapta Therapeutics since January 2024. Prior experience includes a role as Director of Translational Sciences at Alaunos Therapeutics, where Matthew led a team focused on TCR-T cell therapies for solid tumors. Matthew's earlier positions include Associate Director at Ziopharm Oncology, where leadership in clinical immune monitoring supported neoantigen-specific therapies, and Senior Scientist at Bellicum Pharmaceuticals, contributing to CAR-T program development. Educational credentials include a PhD in Translational Biology and Molecular Medicine from Baylor College of Medicine and a BS in Biochemistry from Augustana College. Additionally, Matthew co-founded enventure.org, a non-profit organization supporting medical entrepreneurs in Houston.
This person is not in any offices
Indapta Therapeutics
1 followers
Indapta Therapeutics is a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple types of cancer.